HanchorBio is pioneering the development of fusion protein for immuno-therapy. The HanchorBio team is developing next generation biologic therapeutics to address the growing immuno-oncology market. HanchorBio’s modular approach of combination therapy has the potential to fundamentally transform the therapeutic modulation of the immune system.

Inmagene Biopharmaceuticals is a clinical stage pharmaceutical company with different in-licensed pipeline focusing on immune-related diseases.

Oncxerna is an oncology therapeutics company focusing on clinical programs that modify the immune system to enhance efficacy of current standards of care and emerging immunotherapy agents.

Kindstar Globalgene Technology, Inc. a large high-end esoteric testing service provider in China, is committed to leading the progress of esoteric testing technologies and services in China and promoting the development and improvement of specialized diagnosis and treatment and personalized medicine.

Zhaoke Ophthalmology, a Guangzhou based biotech company, specializeds in developing a porfolio of drugs to treat various eye diseases .

Maaverx is a gene therapy company basd in London. Maaverx focuses on developing treatement for Parkinson’s Disease.

Tactiva Therapeutics is an immuno-oncology company utilizing an innovative approach to adoptive cell therapy.  Tactiva Therapeutics has identified a library of T cell receptors (TCRs) that specifically recognize and attack cancer cells.

Evox Therapeutics is a privately held, Oxford-based biotechnology company focused on harnessing and engineering the natural delivery capabilities of extracellular vesicles, known as exosomes, to develop an entirely new class of therapeutics.

Windtree is a global acute care company specializing in cardiovascular and respiratory diseases.  The company has four mid-to-late cliniacal stage assets and multiple preclinical assets and programs.  Windtree is headquartered in Warrington, PA with pre-clinical operations in Taipei and Milan.

APMTD specializes in designing and developing minimally invasive device solutions for unmet medical needs such as stroke, heart failure, eCPR and peripheral vascular diseases. The company's local drug delivery system TAPAS and targeted hypothermia induction system DuoFlo have been approved for commercialization in US, China, EU, Australia and Taiwan region.

TriArm Therapeutics develops most unique cell therapies for both blood and solid tumors. TriArm established advanced technologies such as Beauty11, DEACT and HiSAFE platform, in which can bring out a series of innovative products with low manufacturing cost, improved safety, and ensured efficacy.

GLAdiator is an early-stage oncology company with a proprietary cancer drug delivery platform that uses the naturally occurring gamma-carboxyglutamic-acid domain associated with human coagulation factors to treat diseased cells through the targeted recognition of phospholipid phosphatidylserine which is believed to be a global immunosuppressive signal.

BioGraph 55 focuses on target discovery and drug development in immuno-oncology by leveraging a proprietary and validated spatial-mapping technology platform that collects biological information from cellular interactions in their native environment and integrates this information with other data to identify novel drug targets.

Actym Therapeutics is an early-stage oncology company with a novel bacterial-based immunotherapy platform that can achieve tumor-specific multi-drug delivery while still utilizing from flexible plasmid design and efficient manufacturing.

Apeiron is a small molecule biotech company based in Shanghai and San Francisco Bay Area, with significant collaborations with Exscientia (NASDAQ: EXIA), an AI drug discovery company based in the UK.

Domain Therapeutics, a biopharmaceutical company operating in France and Canada, is dedicated to the discovery and development of new drug candidates targeting G Protein-Coupled Receptors (GPCRs). The company focuses on developing high-value drug candidates to tackle GPCR-mediated immunosuppression in immune-oncology.

ST Phi Therapeutics，is a Hangzhou based biotech company focused on universal cell therapy development in solid tumors, founded by Dr. Lingfeng Liu.  It is the first biotech to enable off-the-shelf CAR-T therapy featuring NK cell characteristics that is less tumor associated antigen dependent, showing initial safety and efficacy in liver cancer patients.

Founded in 2019, NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for metabolic diseases and Alzheimer's disease.